Drug Development Pharma - October 21, 2014
Clanotech receives orphan drug designation in the EU
Clanotech AB’s anti-fibrotic and anti-angiogenic candidate drug CLT-28643 has received orphan drug designation by the European Medicines Agency (EMA) for prevention of scarring post glaucoma filtration surgery. Clanotech’s lead substance, an α5β1-integrin antagonist, has anti-angiogenic, anti-fibrotic and anti-inflammatory properties that are expected to benefit the wound healing processes following glaucoma surgery, according to the company. […]
Pharma Business - October 20, 2014
Recipharm to be divided
The main shareholders are implementing a division of their shareholdings in Recipharm. B&E Participation AB owns 12,685,716 shares series A and 3,892,407 shares series B in Recipharm, corresponding to approximately 46 percent of the capital and about 86 percent of the votes. Backsell Eldered Holding AB owns all the shares in B&E Participation AB. Lars […]
Drug Development Pharma - October 17, 2014
FIT Biotech to develop Ebola vaccine
Finnish biotechnology company FIT Biotech Oy will together with Icosagen AS develop a new Ebola vaccine. The product development work is based on patented technologies allowing induction of passive and active immunotherapy, states FIT Biotech. The parties will also collaborate with international partners from France and Switzerland. The clinical stage is exepected to start at […]
Collaboration - October 17, 2014
AstraZeneca, MedImmune and the University of Cambridge in new collaborations
AstraZeneca, together with its global biologics research and development arm, MedImmune, has entered into four new collaborations with the University of Cambridge, building further on their existing partnership. The new agreements build on the existing partnership between AstraZeneca, MedImmune and the University of Cambridge, which includes an oncology research programme and co-location of AstraZeneca scientists […]
Agreement - October 16, 2014
Xbrane in Indian agreement
Xbrane Bioscience has signed an agreement with an Indian company in helping them to develop a bacterial system for protein production. Under the agreement, Xbrane will develop a system for the manufacturing of a biosimilar protein pharmaceutical. In an interview with Kemivärlden Biotech Xbrane Biosciences’ CEO Siavash Bashiri says that they cannot reveal which pharmaceutical […]
Financing - October 16, 2014
Forward Pharma prices IPO of ADSs
Danish Forward Pharma A/S has announced the pricing of its initial public offering of 10,500,000 American Depositary Shares, ADSs. The ADSs represent the biopharmaceutical’s ordinary shares at a price to the public of USD 21.00 per ADS. The share were expected to begin trading on October 15 on the NASDAQ Global Select Market under the ticker […]
